3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
7
Hodgkin Disease
6
Lymphoma, Large B-Cell, Diffuse
5
Triple Negative Breast Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma
4
Rhabdomyosarcoma
3
Lymphoma, Non-Hodgkin
3
Leukemia
3
Burkitt Lymphoma
3
Sarcoma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Neuroblastoma
2
Multiple Myeloma
2
Fallopian Tube Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Teratoma
1
Squamous Cell Carcinoma of Head and Neck
1
Sleep Initiation and Maintenance Disorders
1
Sarcoma, Ewing
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Pancreatic Neoplasms
1
Pain
1
Interventions
Etoposide
7
Cisplatin
7
fludarabine
4
Cyclophosphamide
4
fludarabine phosphate
3
Paclitaxel
3
Carboplatin
3
Bleomycin
3
Automobiles
3
pembrolizumab
2
etoposide phosphate
2
Vorinostat
2
Sirolimus
2
Mesna
2
Ifosfamide
2
Drug Therapy
2
130-nm albumin-bound paclitaxel
2
tremelimumab
1
tozuleristide
1
sodium thiosulfate
1
repotrectinib
1
pralsetinib
1
pegfilgrastim
1
lutetium Lu 177 dotatate
1
durvalumab
1
cabozantinib
1
Watchful Waiting
1
Teniposide
1
Surveys and Questionnaires
1
Stem Cell Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Germ Cell and Embryonal
×
pegfilgrastim
×
1 year
×
Clear all
NCT02582697
2025-06-15
P3BEP
University of Sydney
Phase 3
Recruiting
500 enrolled